Physician profile
Tamer Atassi
NPI 1548276819
$3,707.53
in general payments reported to CMS, 2019-2025
24 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $31.48 · 2021: $81.39 · 2022: $355 · 2023: $1,074 · 2024: $973 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994 · Education: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.69 |
| Education | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,307.71 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $364.85 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $257.69 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $197.57 | 2024-2025 | |
| Boston Scientific Corporation | $192.01 | 2021-2024 | Exalt Model D |
| Medtronic, INC. | $168.08 | 2023 | Endoflip |
| Merck Sharp & Dohme LLC | $135.11 | 2023 | Dificid, Zinplava |
| Conmed Corporation | $134.46 | 2024 | Conmed Hemostasis, Conmed Generators |
| Intuitive Surgical, INC. | $132.80 | 2025 | |
| Sandoz INC. | $124.02 | 2023-2024 | Hyrimoz |
| Pinnacle Biologics, INC | $115.81 | 2024 | Photofrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.03 | 2023-2024 | Trulance, Xifaxan |
| Ardelyx, INC. | $77.78 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $77.53 | 2023-2025 | Sucraid |
| Genzyme Corporation | $50.29 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $48.99 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $47.74 | 2025 | Zenpep, Vowst |
| Celgene Corporation | $41.95 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $32.93 | 2024 | Resmetirom |
| Mauna Kea Technologies, INC. | $31.02 | 2019-2020 | |
| Allergan, INC. | $24.39 | 2019 | |
| Evoke Pharma, INC. | $22.45 | 2024 | |
| Novo Nordisk INC | $21.58 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamer Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.